Gilead is committed to making its products available for treatment and prevention research in the developing world. It provides its HIV medicine at no cost for use in multiple clinical studies and works with healthcare organizations, patient advocacy groups and public health institutions to raise awareness and increase diagnosis and treatment of HIV/AIDS.

Gilead partners with organizations such as the Bill and Melinda Gates Foundation, Family Health International, the UK Medical Research Council, the US Centers for Disease Control and Prevention (CDC) and France´s Agence Nationale de Recherches sur le SIDA (ANRS), providing its products for more than 20 clinical studies that will together enroll more than 10,000 patients in Africa, Asia and Latin America. The largest of these studies is the “Development of Antiretroviral Therapy” (DART) study with two sites in Uganda and one site in Zimbabwe. To date, the company has committed more than 50,000 patient-years worth of medicines for developing world research.

In addition, multiple pre-exposure prophylaxis studies with once-daily Viread® and Truvada® are ongoing, sponsored by the US Centers for Disease Control, Family Health International and other third-party organizations. Gilead has other development programs in HIV, including an HIV integrase inhibitor, as well as programs in hepatitis B and hepatitis C.